MOZ-TIF2, but Not BCR-ABL, Confers Properties of Leukemic Stem Cells to Committed Murine Hematopoietic Progenitors.
Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Gary Gilliland(Boston Biomedical Research Institute), Hirokazu Shigematzu(Harvard University), Nicky Duclos(Brigham and Women's Hospital), Ifor R. Williams(Emory University), Shinichi Mizuno(Sendai Shakai Hoken Hospital), Benjamin J. Lee(Chapman University), Koichi Akashi(Kyushu University), R. M. Rowan(Queen's University Belfast), David P. Curley(Massachusetts General Hospital), Kenji Deguchi(Brigham and Women's Hospital), Sonia M Amaral(Brigham and Women's Hospital)
Cited by 5
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k